Nontraumatic subarachnoid hemorrhage remains one of the most common cardiovascular and neurological causes of death and disabilities in the world.

GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) will soon submit its new drug application (NDA) ...

New therapies for cerebral vasospasm after subarachnoid hemorrhage are needed because of its high morbidity ... Patients were approached for consent if they met the following inclusion criteria: ...